Close Menu


In a new study, researchers used base editing to extend the lives of mice with a premature aging syndrome.

Growth was driven by demand in its life science segment, particularly for COVID-19-related products, while the diagnostics segment saw uneven improvement.

The bill, which Congress overwhelmingly approved last week, also includes additional funding for the US Centers for Disease Control and Prevention.

The bill, which was overwhelming passed by both the Senate and the House, would boost the National Institutes of Health's budget by $1.25 billion.

The agency also helped fund the development of the Revogene SARS-CoV-2 assay, which detects RNA targets directly from viral transport media without pre-dilution.

The program received an IDE from the FDA this summer and plans to release its first batch of genetic data to the research community late next year.

The company said it will use the funding to integrate Oxford Nanopore Technologies' ultra-long read genomic sequencing into its service.

Early data from Moderna suggests its candidate SARS-CoV-2 vaccine is highly effective, writes the Washington Post.

Fluidigm tallied $39.9 million in revenues compared to $26.5 million a year ago, and well above analysts' consensus estimate of $32.5 million.

The CRISPR-based test uses Mammoth's DETECTR BOOST platform and will be compatible with both nasal swab and saliva samples.


Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.